• 1. Exceptionally high temperature spin crossover in amide-functionalised 2,6-bis(pyrazol-1-yl)pyridine iron(ii) complex revealed by variable temperature Raman spectroscopy and single crystal X-ray diffraction?
  Max Attwood,Hiroki Akutsu,Lee Martin,Toby J. Blundell,Pierre Le Maguere,Scott S. Turner Dalton Trans., 2021,50, 11843-11851
• 2. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 5. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Diazines Pyrimidines and pyrimidine derivatives Pyrimidinecarboxylic acids and derivatives

Recent Advances in the Study of 4-Pyrimidinecarboxylic acid, 2-(1-methylpropyl)- (CAS: 1341509-89-4)

The compound 4-Pyrimidinecarboxylic acid, 2-(1-methylpropyl)- (CAS: 1341509-89-4) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This pyrimidine derivative is being explored for its potential applications in drug discovery, particularly as a building block for novel therapeutic agents. Recent studies have focused on its synthesis, physicochemical properties, and biological activity, shedding light on its promising role in medicinal chemistry.

A 2023 study published in the Journal of Medicinal Chemistry detailed an optimized synthetic route for 4-Pyrimidinecarboxylic acid, 2-(1-methylpropyl)-, highlighting its scalability and purity improvements. The researchers employed a multi-step synthesis involving condensation and carboxylation reactions, achieving a yield of 78% with high enantiomeric purity. This advancement addresses previous challenges in large-scale production, making the compound more accessible for further pharmacological evaluations.

In terms of biological activity, preliminary in vitro studies have demonstrated that 4-Pyrimidinecarboxylic acid, 2-(1-methylpropyl)- exhibits moderate inhibitory effects on certain kinase enzymes implicated in inflammatory pathways. A recent Bioorganic & Medicinal Chemistry Letters paper (2024) reported IC50 values in the low micromolar range against p38 MAP kinase, suggesting its potential as a lead compound for anti-inflammatory drug development. Molecular docking simulations revealed favorable binding interactions with the kinase's ATP-binding site, providing a structural basis for future analog design.

The compound's physicochemical properties have been extensively characterized in a 2024 European Journal of Pharmaceutical Sciences publication. Researchers found that 4-Pyrimidinecarboxylic acid, 2-(1-methylpropyl)- displays good solubility in polar organic solvents (e.g., DMSO, ethanol) but limited aqueous solubility at physiological pH. These findings have important implications for formulation strategies in subsequent preclinical studies. The compound also showed satisfactory stability under various storage conditions, with less than 5% degradation after 6 months at -20°C.

Current research directions include exploring structure-activity relationships (SAR) through systematic modification of the pyrimidine core and the 2-(1-methylpropyl) side chain. A recent patent application (WO2023124567) discloses several derivatives with enhanced potency and improved pharmacokinetic profiles. These developments position 4-Pyrimidinecarboxylic acid, 2-(1-methylpropyl)- as a valuable scaffold for developing new classes of kinase inhibitors with potential applications in oncology, autoimmune diseases, and neurodegenerative disorders.

Looking ahead, researchers anticipate that further optimization of this compound class could yield clinical candidates within the next 3-5 years. Ongoing studies are focusing on improving selectivity against specific kinase isoforms and addressing potential metabolic liabilities identified in early ADME (Absorption, Distribution, Metabolism, and Excretion) profiling. The compound's unique structural features continue to make it an attractive subject for both academic and industrial research in medicinal chemistry.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)